OptimizeRx Corporation
NASDAQ:OPRX
6.6 (USD) • At close October 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 71.522 | 62.45 | 61.293 | 43.313 | 24.598 | 21.206 | 12.127 | 7.751 | 7.221 | 6.503 | 4.957 | 2.049 | 1.112 | 0.071 | 0.027 | 0.084 | 0.1 |
| Cost of Revenue
| 28.622 | 23.483 | 25.654 | 19.208 | 9.159 | 9 | 6.175 | 3.411 | 3.622 | 3.222 | 1.767 | 0.115 | 0 | 0 | 2.647 | 0 | 0 |
| Gross Profit
| 42.9 | 38.967 | 35.638 | 24.105 | 15.44 | 12.207 | 5.953 | 4.34 | 3.598 | 3.281 | 3.19 | 1.933 | 1.112 | 0.071 | -2.62 | 0.084 | 0.1 |
| Gross Profit Ratio
| 0.6 | 0.624 | 0.581 | 0.557 | 0.628 | 0.576 | 0.491 | 0.56 | 0.498 | 0.505 | 0.643 | 0.944 | 1 | 1 | -98.055 | 1 | 1 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 1.081 | 2.672 | 0.676 | 1.009 | 0.398 | 0.29 | 0.19 | 0.13 | 0.127 | 0 | 0.078 | 0 | 0 | 0 |
| General & Administrative Expenses
| 58.02 | 49.236 | 33.191 | 24.165 | 17.85 | 11.71 | 7.758 | 4.941 | 3.274 | 3.367 | 2.733 | 2.169 | 2.021 | 1.532 | 1.727 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 1.029 | 0.616 | 0.709 | 0.3 | 0.207 | 0.297 | 0.048 | 0.087 | 0.047 | 0.057 | 0.544 | 0.188 | 0.669 | 0 | 0 |
| SG&A
| 58.02 | 49.236 | 33.191 | 24.165 | 17.85 | 11.71 | 7.758 | 5.238 | 3.322 | 3.454 | 2.78 | 2.226 | 2.565 | 1.72 | 2.396 | 0 | 0 |
| Other Expenses
| 0.5 | 2.022 | 2.086 | 0.995 | -1.39 | 0.449 | 0.325 | 0.235 | 0.584 | 0.264 | 0.194 | 0.187 | 2.565 | 0.119 | 0.278 | 1.592 | 0.456 |
| Operating Expenses
| 60.422 | 51.258 | 35.277 | 26.241 | 19.133 | 12.027 | 8.083 | 5.872 | 4.196 | 3.908 | 2.974 | 2.413 | 2.565 | 1.917 | 2.674 | 1.592 | 0.456 |
| Operating Income
| -26.402 | -12.291 | 0.482 | -1.89 | -3.694 | 0.18 | -2.13 | -1.582 | -0.597 | -1.026 | 0.216 | -0.364 | -1.454 | -1.846 | -2.647 | -1.508 | -0.356 |
| Operating Income Ratio
| -0.369 | -0.197 | 0.008 | -0.044 | -0.15 | 0.008 | -0.176 | -0.204 | -0.083 | -0.158 | 0.043 | -0.178 | -1.308 | -25.979 | -99.055 | -18.02 | -3.548 |
| Total Other Income Expenses Net
| -8.38 | 0.852 | -0.104 | -0.317 | -0.347 | -0.608 | 0.026 | -0.05 | 0.002 | -0.4 | 0 | 0 | 0.291 | -0.059 | -1.938 | -2.745 | -0.006 |
| Income Before Tax
| -25.164 | -11.438 | 0.378 | -2.207 | -4.041 | 0.226 | -2.104 | -1.539 | -0.595 | -1.025 | 0.216 | -0.364 | -2.121 | -2.009 | -4.556 | -4.249 | -0.361 |
| Income Before Tax Ratio
| -0.352 | -0.183 | 0.006 | -0.051 | -0.164 | 0.011 | -0.173 | -0.199 | -0.082 | -0.158 | 0.044 | -0.178 | -1.908 | -28.27 | -170.478 | -50.771 | -3.603 |
| Income Tax Expense
| -7.598 | -0.852 | 0.104 | 0.177 | -0.898 | 0.046 | 0 | 0 | 0.002 | 0 | 0 | 0 | 0.959 | 0.166 | 0.001 | 0.001 | 0 |
| Net Income
| -17.566 | -10.586 | 0.274 | -2.384 | -3.143 | 0.226 | -2.104 | -1.539 | -0.595 | -1.025 | 0.216 | -0.364 | -2.121 | -2.009 | -4.556 | -4.249 | -0.361 |
| Net Income Ratio
| -0.246 | -0.17 | 0.004 | -0.055 | -0.128 | 0.011 | -0.173 | -0.199 | -0.082 | -0.158 | 0.044 | -0.178 | -1.908 | -28.27 | -170.478 | -50.771 | -3.603 |
| EPS
| -1.03 | -0.6 | 0.016 | -0.16 | -0.23 | 0.02 | -0.21 | -0.16 | -0.073 | -0.14 | -0.06 | -0.077 | -0.46 | -0.46 | -1.09 | -1.06 | -0.52 |
| EPS Diluted
| -1.03 | -0.6 | 0.016 | -0.16 | -0.23 | 0.019 | -0.21 | -0.16 | -0.073 | -0.14 | -0.06 | -0.077 | -0.46 | -0.46 | -1.09 | -1.06 | -0.52 |
| EBITDA
| -12.428 | -10.269 | 2.448 | 0.081 | -1.776 | 0.497 | -1.805 | -1.254 | -0.261 | -0.361 | 0.41 | -0.177 | -1.307 | -1.724 | -2.584 | -1.471 | -0.353 |
| EBITDA Ratio
| -0.174 | -0.164 | 0.04 | 0.002 | -0.072 | 0.023 | -0.149 | -0.162 | -0.036 | -0.056 | 0.083 | -0.086 | -1.176 | -24.264 | -96.709 | -17.575 | -3.52 |